{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:51:33Z","timestamp":1791179493638,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Serum uric acid (SUA) has been implicated in various inflammatory conditions, yet its association with inflammatory proteins and treatment outcomes in psoriasis remains unclear. This study aimed to investigate the association of SUA levels with specific circulating inflammatory proteins and treatment response to ixekizumab, a monoclonal antibody against interleukin-17A, in patients with moderate-to-severe psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients attending 26 dermatology centers across China were recruited into this real-world prospective cohort study conducted between August 2020 and May 2022. The SUA levels of the participants were measured to assess hyperuricemia, and treatment response was evaluated using the Psoriasis Area and Severity Index (PASI). All participants received ixekizumab at a dose of 160 mg at week 0, followed by 80 mg every 2 weeks through week 12. Adjusted logistic regression analysis was used to explore differences in treatment response between patients with and without hyperuricemia. The restricted cubic spline (RCS) was employed to explore the continuous relationship between SUA and the response outcomes. Specifically, we measured 92 circulating plasma inflammatory markers using the Olink Proteomics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 390 patients with psoriasis were included in the study. The psoriasis patients with hyperuricemia demonstrated a higher prevalence of obesity, hyperlipidemia, and hyperglycemia compared with those without hyperuricemia. After 12 weeks of ixekizumab treatment, patients with hyperuricemia exhibited a lower likelihood of achieving PASI 75 (adjusted odds ratio [aOR] 0.84, 95% confidence interval [CI] 0.69\u20130.99), PASI 90 (aOR 0.37, 95% CI 0.15\u20130.62), and PASI 100 (aOR 0.57, 95% CI 0.37\u20130.91). Olink Proteomics identified significant correlations between SUA concentration and the levels of 26 circulating inflammatory proteins, and pathway analysis showed enrichment of pathways such as response to tumor necrosis factor (TNF), lymphocyte activation, and cytokine activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Elevated SUA levels can hinder the effectiveness of ixekizumab and positively correlate with specific circulating inflammatory proteins in patients with psoriasis, emphasizing the need for further investigation and consideration of metabolic factors in psoriasis management strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registeration:<\/jats:title>\n                    <jats:p>Chinese Clinical Trial Registry (ChiCTR2000036186)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004261","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:00:08Z","timestamp":1787626808000},"page":"2930-2937","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Association of serum uric acid with circulating inflammatory proteins and treatment response to ixekizumab in patients with psoriasis: A multicenter prospective cohort study in China"],"prefix":"10.1097","volume":"139","author":[{"given":"Yuxiong","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuolin","family":"Guo","sequence":"additional","affiliation":[{"name":"Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Yao","sequence":"additional","affiliation":[{"name":"Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[{"name":"Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajing","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China"},{"name":"Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China"},{"name":"Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China"},{"name":"Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"R1-20261005","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/CM9.0000000000002504","article-title":"Research progress of metabolomics in psoriasis","volume":"136","author":"Guo","year":"2023","journal-title":"Chin Med J"},{"key":"R2-20261005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102916","article-title":"Pathogenesis, multi-omics research, and clinical treatment of psoriasis","volume":"133","author":"Yu","year":"2022","journal-title":"J Autoimmun"},{"key":"R3-20261005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: Focus on psoriasis comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"R4-20261005","article-title":"Updated evidence of the association between elevated serum uric acid level and psoriasis","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R5-20261005","article-title":"The dysregulation of immune cells induced by uric acid: Mechanisms of inflammation associated with hyperuricemia and its complications","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"R6-20261005","doi-asserted-by":"crossref","first-page":"12537","DOI":"10.1038\/s41598-023-39775-2","article-title":"Hyperuricemia is accompanied by elevated peripheral CD4+ T cells","volume":"13","author":"Yu","year":"2023","journal-title":"Sci Rep"},{"key":"R7-20261005","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/CM9.0000000000002390","article-title":"Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis","volume":"136","author":"Huang","year":"2023","journal-title":"Chin Med J"},{"key":"R8-20261005","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1097\/CM9.0000000000002873","article-title":"Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension","volume":"137","author":"Yu","year":"2024","journal-title":"Chin Med J"},{"key":"R9-20261005","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/CM9.0000000000002683","article-title":"Prevalence of psoriatic arthritis in Chinese population with psoriasis: A multicenter study conducted by experienced rheumatologists","volume":"136","author":"Zhang","year":"2023","journal-title":"Chin Med J"},{"key":"R10-20261005","doi-asserted-by":"crossref","DOI":"10.1002\/prca.202300233","article-title":"Methods and clinical biomarker discovery for targeted proteomics using Olink technology","volume":"18","author":"Wang","year":"2024","journal-title":"Proteomics Clin Appl"},{"issue":"W1","key":"R11-20261005","doi-asserted-by":"crossref","first-page":"W60","DOI":"10.1093\/nar\/gky311","article-title":"GeneMANIA update 2018","volume":"46","author":"Franz","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"R12-20261005","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1097\/CM9.0000000000003024","article-title":"Clinical characteristics and outcomes of psoriasis patients with COVID-19: A retrospective, multicenter cohort study in China","volume":"137","author":"Liu","year":"2024","journal-title":"Chin Med J"},{"key":"R13-20261005","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/1346-8138.13968","article-title":"Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients","volume":"44","author":"Tsuruta","year":"2017","journal-title":"J Dermatol"},{"key":"R14-20261005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41420-024-01900-z","article-title":"Uric acid-driven NLRP3 inflammasome activation triggers lens epithelial cell senescence and cataract formation","volume":"10","author":"Lin","year":"2024","journal-title":"Cell Death Discov"},{"key":"R15-20261005","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111932","article-title":"Signaling pathways in uric acid homeostasis and gout: From pathogenesis to therapeutic interventions","volume":"132","author":"Yang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R16-20261005","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/bjd\/ljae147","article-title":"Insulin resistance impairs biologic agent response in moderate-to-severe plaque psoriasis: Insights from a prospective cohort study in China","volume":"191","author":"Huang","year":"2024","journal-title":"Br J Dermatol"},{"key":"R17-20261005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2018.03.045","article-title":"Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan","volume":"261","author":"Kuwabara","year":"2018","journal-title":"Int J Cardiol"},{"key":"R18-20261005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11154-023-09787-4","article-title":"Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond","volume":"24","author":"Yu","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"key":"R19-20261005","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.3390\/nu13093015","article-title":"Biologic treatment in combination with lifestyle intervention in moderate to severe plaque psoriasis and concomitant metabolic syndrome: Rationale and methodology of the METABOLyx randomized controlled clinical trial","volume":"13","author":"Pinter","year":"2021","journal-title":"Nutrients"},{"key":"R20-20261005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2021.06.883","article-title":"Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry","volume":"86","author":"Enos","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R21-20261005","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.numecd.2023.10.008","article-title":"Association between systemic immune-inflammation index and serum uric acid in U.S. adolescents: A population-based study","volume":"34","author":"Xie","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R22-20261005","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1097\/CM9.0000000000002748","article-title":"Clinical features of Chinese psoriatic patients for early referral of arthritis using psoriasis epidemiology screening tool: A cross-sectional analysis from the registry database of Chinese Psoriasis Standardized Diagnosis and Treatment Center","volume":"136","author":"Xia","year":"2023","journal-title":"Chin Med J"},{"key":"R23-20261005","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1097\/CM9.0000000000002563","article-title":"Updates in psoriasis diagnosis and treatment status in China: Results from the National Psoriasis Center Registry","volume":"136","author":"Yang","year":"2023","journal-title":"Chin Med J"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:00:13Z","timestamp":1791176413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":23,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004261","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"2025-07-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}